Two new achievements of traditional Chinese medicine research in the University of medicine "sold" 100 million yuan

It is the first time to find the therapeutic effect of pentacyclic triterpenoids on Alzheimer's disease, and the first time to find that Radix Ophiopogonis has inhibitory and killing effects on tumor The reporter recently learned from the 2014 science and Technology Conference of China Pharmaceutical University that the research results of teachers have been sought after by many manufacturers, among which two innovative researches on traditional Chinese medicine have been "bought" by enterprises at a high price of more than 100 million yuan, setting the highest price in Jiangsu Province for the transfer fee of single research results on traditional Chinese medicine One of the two new achievements of traditional Chinese medicine research is named as "ASD compound anti ad traditional Chinese medicine class I new drug", with a transfer fee of 110 million yuan "ASD is a natural product of pentacyclic triterpenoids." Yang Zhonglin, a professor at the College of traditional Chinese medicine, the research leader, said ad is Alzheimer's disease The research shows that ASD has both the preventive and therapeutic effects on AD This research has been carried out for more than ten years, and the innovation lies in: it is the first time to find that ASD has the active role in the treatment of Alzheimer's disease; it is found that ASD can treat Alzheimer's disease by regulating a β; the preparation process of ASD only involves resin, ethanol and water, which is suitable for industrial production "The prospect of extracting new drugs from traditional Chinese medicine is very broad." Yang Zhonglin told reporters that it will take more than 10 years to develop a new drug in the world, which will cost more than one billion dollars The research is from mice and rats to larger animals, and then to clinic The traditional Chinese medicine has thousands of years of clinical practice, which is directly eaten by people, with guaranteed safety and relatively reliable curative effect "China's aging rate is at the forefront of the world, with a high incidence of Alzheimer's disease, but there is no ideal treatment drug in clinical practice The social and economic significance of this drug development is quite great " The project is undergoing pre clinical supplement and improvement research, which has been transferred to Jiangsu Kangyuan Pharmaceutical Co., Ltd., a famous Chinese medicine enterprise, and it will take 5-8 years to enter the market Another achievement is called "dt-13, a new type of new anti-tumor and metastasis traditional Chinese medicine", which was "won" by tisley Pharmaceutical Group Co., Ltd., one of the leading enterprises of traditional Chinese medicine, with 100 million yuan Yu Boyang, the project leader and professor of the College of traditional Chinese medicine, told reporters that during the long-term research on common Chinese medicine of Ophiopogon japonicus, the research team found that the leading compound dt-13 not only can inhibit the metastasis of tumor, but also has a killing effect on tumor cells At present, the drug is in the stage of clinical research, and it is expected to apply for clinical approval of new drugs in 2015.